Latest news

• Celgene, Agios get FDA OK for leukaemia drug Idhifa

  Idhifa ( enasidenib or AG-221) has been cleared for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in patients with an IDH2 mutation, a group that accounts for somewhere ... At Celgene, enasidenib will slot into its blood cancer

• Celgene bags US priority review for cancer metabolism drug

  First approval for enasidenib could be just six months away. Celgene could be just six months away from getting its first approval for enasidenib, a first-in-class drug for acute ... Celgene filed for approval of enasidenib as a treatment for relapsed,